Back to School: How biopharma can reboot drug development. Access exclusive analysis here
In a 99-patient, open label trial of rhuMAb-VEGF in combination with carboplatin and paclitaxel, 22 percent of
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury